Dermata Therapeutics Inc. (DRMA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dermata Therapeutics Inc. (DRMA:NASDAQ), powered by AI.

Current Price
$1.19
Sector
Healthcare
What is the Dermata Therapeutics Inc. stock price forecast?

Dermata Therapeutics Inc. is currently trading at $1.19. View real-time AI analysis on Alpha Lenz.

What is Dermata Therapeutics Inc. insider trading activity?

View the latest insider trading data for Dermata Therapeutics Inc. on Alpha Lenz.

What is Dermata Therapeutics Inc.'s P/E ratio?

View Dermata Therapeutics Inc.'s valuation metrics on Alpha Lenz.

Dermata Therapeutics Inc.

NASDAQ · DRMA
$1.19-0.01(-0.83%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Dermata Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Dermata Therapeutics Inc.'s ROE is -194.2%. Explore profitability and growth together.

Ask for details

Company Overview

Dermata Therapeutics Inc. is a clinical-stage biotechnology company committed to developing and commercializing pharmaceutical solutions for dermatological conditions. The company's core focus is on creating innovative therapies to address unmet medical needs within dermatology, with a particular emphasis on skin diseases like acne, rosacea, and psoriasis. Dermata's proprietary technology aims to improve the efficacy and safety profiles of topical treatments, which are critical for patient compliance and therapeutic success. Through its research and development efforts, Dermata impacts the healthcare sector by seeking to enhance the quality of life for individuals with dermatological conditions. Its contribution is significant in pinpointing novel drug candidates that might advance clinical standards and offer alternative treatment modalities. Dermata Therapeutics Inc. plays an important role in the biopharmaceutical industry by advancing science-driven solutions that address complex challenges within the field of dermatology.

CEOMr. Gerald T. Proehl
SectorHealthcare
IndustryBiotechnology
Employees8

Company Statistics

FY 2025

Profile

N/AMarket Cap
$0.00Revenue
0.00Shares Out
8Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-132.63%ROA
-194.20%ROE
-136.41%ROIC

Financial Health

$7.52MCash & Cash Equivalents
$-5.88MNet Debt
26.36%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Dermata Therapeutics Inc. (ticker: DRMA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 8 employees.

The current price is $1.19 with a P/E ratio of -x and P/B of -x.

ROE is -194.20%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Dermata Therapeutics Inc. (DRMA) Stock Forecast 2026 $1.19 — Price, Financials & Analyst Targets | Alpha Lenz